Evotec AG (NASDAQ:EVO) Receives Average Rating of “Hold” from Analysts

Evotec AG (NASDAQ:EVO) has been assigned an average recommendation of “Hold” from the five analysts that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and two have issued a buy recommendation on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $3.00.

EVO has been the subject of several research analyst reports. Berenberg Bank cut Evotec from a “buy” rating to a “hold” rating in a report on Thursday, July 16th. HC Wainwright lowered their target price on Evotec from $7.00 to $4.00 and set a “buy” rating for the company in a research report on Wednesday, July 15th. Wall Street Zen lowered shares of Evotec from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Weiss Ratings upgraded shares of Evotec from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, April 24th. Finally, TD Cowen downgraded shares of Evotec from a “buy” rating to a “hold” rating and set a $2.00 price target on the stock. in a research note on Wednesday, July 15th.

Evotec Stock Performance

EVO opened at $1.98 on Tuesday. The firm has a 50-day simple moving average of $2.72 and a two-hundred day simple moving average of $3.00. Evotec has a 52 week low of $1.95 and a 52 week high of $4.42. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.68 and a quick ratio of 1.60.

Institutional Trading of Evotec

A number of large investors have recently made changes to their positions in the business. XTX Topco Ltd lifted its stake in shares of Evotec by 25.1% in the 4th quarter. XTX Topco Ltd now owns 18,469 shares of the company’s stock valued at $57,000 after purchasing an additional 3,709 shares during the last quarter. BNP Paribas Financial Markets increased its position in shares of Evotec by 62.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 12,000 shares of the company’s stock valued at $50,000 after purchasing an additional 4,600 shares during the last quarter. Bank of America Corp DE increased its position in shares of Evotec by 262.5% during the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock valued at $53,000 after purchasing an additional 9,289 shares during the last quarter. Apollon Wealth Management LLC purchased a new stake in Evotec during the 1st quarter valued at $28,000. Finally, Marshall Wace LLP purchased a new stake in Evotec during the 4th quarter valued at $40,000. 5.81% of the stock is currently owned by institutional investors.

Evotec Company Profile

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.